You are here
Epizyme Announces Date of Second Quarter 2018 Financial Results and Business Update Conference Call
CAMBRIDGE, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report its second quarter 2018 financial results on Thursday, August 2, 2018. Management will host a conference call and webcast that morning at 8:30 a.m. ET to discuss these results and other business updates.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5734199. A live webcast will be available in the investor section of the company's website at http://www.epizyme.com. The webcast also will be archived for 60 days following the call.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Erin Graves, Epizyme, Inc.
Jason Fredette, Epizyme, Inc.